BUSINESS COMBINATION - Purchase Price Allocation (Details) - USD ($) $ in Thousands			6 Months Ended
	Jun. 16, 2016	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
Business Acquisition [Line Items]
Cash paid upon consummation			$ 500	$ 33,430
Liquid Ursodeoxycholic Acid (L-UDCA) [Member]
Business Acquisition [Line Items]
Cash paid upon consummation	$ 500
Present value of contingent consideration and service fees	25,000
Total Purchase Price	25,500
Fair Value of Assets Acquired and Liabilities Assumed
Acquired product rights- (Intangible Asset)	25,500
Total Allocation of Purchase Price	$ 25,500
Asklepion Pharmaceuticals, LLC
Business Acquisition [Line Items]
Common stock shares issued (in shares)		661,279
Cash paid upon consummation		$ 33,430
Present value of contingent consideration and service fees		42,010
Fair Value of 661,279 shares issued to Asklepion		15,844
Total Purchase Price		91,284
Fair Value of Assets Acquired and Liabilities Assumed
Acquired product rights- (Intangible Asset)		83,200
Pediatric Priority Review Voucher		96,250
Inventory		777
Deferred tax liability		(39,880)
Total Allocation of Purchase Price		140,347
Bargain Purchase Gain		(49,063)
Total Purchase Price		$ 91,284